Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema.
Sign Up to like & getrecommendations! Published in 2022 at "Allergy and asthma proceedings"
DOI: 10.2500/aap.2022.43.220016
Abstract: Background: Hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency is a rare genetic disorder characterized by disabling episodes of edema that commonly affect the skin as well as the gastrointestinal tract and upper airway. Prophylactic… read more here.
Keywords: subcutaneous inhibitor; hereditary angioedema; symptom control; prophylactic therapy ... See more keywords